BioNxt Solutions同意获得对先进的监护技术的专属权,以提高药物的提供和有效性。 BioNxt Solutions agreed to acquire exclusive rights to advanced chaperone technology to improve drug delivery and effectiveness.

2026年2月5日,BioNxt Solutions Inc.宣布了一项不具约束力的协议,从一家第三方生物技术公司获得对高级监护人技术的专属权。 BioNxt Solutions Inc. announced on February 5, 2026, a non-binding agreement to acquire exclusive rights to advanced chaperone technology from a third-party biotech firm. 该技术在不改变化学结构的情况下增强药物稳定性和吸收能力,目的是改进BioNxt口服薄膜平台的性能,特别是用于次语种和泡泡输送。 The technology, which enhances drug stability and absorption without altering chemical structure, is intended to improve the performance of BioNxt’s oral thin-film platform, particularly for sublingual and buccal delivery. 这一行动旨在扩大治疗神经、自体免疫、传染病和肿瘤病的药物的重新配制选择,为病人坚持治疗和坚持服药带来潜在好处。 The move aims to expand reformulation options for drugs treating neurological, autoimmune, infectious, and oncology conditions, with potential benefits for patient adherence and consistent dosing. 该交易有待达成最后协议。 The transaction is pending final agreements.